Salarius Pharmaceuticals, Inc. (SLRX) Announces Proposed Public Offering of Common Stock

Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Salarius. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager in connection with the public offering.

A shelf registration statement on Form S-3 (File No. 333-231010) relating to the shares was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on May 17, 2019.

You May Also Be Interested In

• EastGroup Properties reports leasing, acquisitions, and new equity deals
• Vaxcyte names new CMO, CLO and narrows VAX-31 data timeline
• Alight names Bruce Wolfe as SVP, Wealth Solution Leader